BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $394,355 | -0.5% | 4,831 | -9.6% | 0.01% | -14.3% |
| Q1 2023 | $396,471 | -22.7% | 5,344 | -13.7% | 0.01% | -22.2% |
| Q4 2022 | $513,193 | -28.0% | 6,192 | +146.6% | 0.01% | -35.7% |
| Q3 2022 | $713,000 | -9.9% | 2,511 | +10.0% | 0.01% | 0.0% |
| Q2 2022 | $791,000 | -7.8% | 2,282 | +15.2% | 0.01% | +7.7% |
| Q1 2022 | $858,000 | -12.6% | 1,981 | +4.3% | 0.01% | -13.3% |
| Q4 2021 | $982,000 | +5.9% | 1,899 | -0.8% | 0.02% | 0.0% |
| Q3 2021 | $927,000 | +4.2% | 1,914 | -3.1% | 0.02% | +7.1% |
| Q2 2021 | $890,000 | +18.4% | 1,976 | +0.3% | 0.01% | +7.7% |
| Q1 2021 | $752,000 | +20.1% | 1,970 | 0.0% | 0.01% | +18.2% |
| Q4 2020 | $626,000 | +28.3% | 1,970 | 0.0% | 0.01% | +10.0% |
| Q3 2020 | $488,000 | -6.2% | 1,970 | 0.0% | 0.01% | -9.1% |
| Q2 2020 | $520,000 | +32.3% | 1,970 | -4.8% | 0.01% | +10.0% |
| Q1 2020 | $393,000 | -13.1% | 2,070 | +0.6% | 0.01% | +25.0% |
| Q4 2019 | $452,000 | +12.4% | 2,057 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $402,000 | -6.7% | 2,057 | -0.4% | 0.01% | -11.1% |
| Q2 2019 | $431,000 | +103.3% | 2,065 | +44.1% | 0.01% | +125.0% |
| Q2 2018 | $212,000 | -50.1% | 1,433 | -49.1% | 0.00% | -55.6% |
| Q1 2018 | $425,000 | -33.5% | 2,814 | -42.9% | 0.01% | -30.8% |
| Q4 2017 | $639,000 | +12.1% | 4,932 | +4.6% | 0.01% | +8.3% |
| Q3 2017 | $570,000 | +0.7% | 4,715 | -2.2% | 0.01% | -7.7% |
| Q2 2017 | $566,000 | +10.8% | 4,820 | -4.2% | 0.01% | +8.3% |
| Q1 2017 | $511,000 | -2.1% | 5,031 | -0.9% | 0.01% | -7.7% |
| Q4 2016 | $522,000 | -7.4% | 5,077 | -1.5% | 0.01% | -7.1% |
| Q3 2016 | $564,000 | -2.1% | 5,155 | +0.9% | 0.01% | -6.7% |
| Q2 2016 | $576,000 | +22.6% | 5,109 | +2.8% | 0.02% | +25.0% |
| Q1 2016 | $470,000 | +53.6% | 4,971 | +46.3% | 0.01% | +50.0% |
| Q4 2015 | $306,000 | – | 3,398 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |